<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546390</url>
  </required_header>
  <id_info>
    <org_study_id>Protect</org_study_id>
    <nct_id>NCT00546390</nct_id>
  </id_info>
  <brief_title>Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study</brief_title>
  <official_title>Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a treatment called remote ischemic preconditioning
      (rIP) to no treatment. rIP is a simple treatment that is believed to help patients recover
      better after heart surgery. This treatment involves applying a large blood pressure cuff to
      one leg. The blood pressure cuffs will be inflated for 5 minutes and then deflated for 5
      minutes. This will be done 4 times in a row.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

        1. Determine, in a pilot study, if surrogate markers of rIP can be detected in patients
           presenting for cardiac surgery. Specifically measure the effect of rIP on the expression
           profile of HSP-70, iNOS, PKC-E, p38 MAPK, PI3K, and sarcolemmal KATP

        2. Determine if rIP influences the expression of genes known to influence substrate
           preference and thereby myocardial metabolism in patients undergoing heart surgery.
           Specifically the expression of HIF-1a, PPAR-a and AMPK

      Hypothesis:

      We hypothesize that rIP provides myocardial protection in patients presenting for heart
      surgery and that this protection is defined by a distinct gene expression profile with
      regards to genes involved in rIP and myocardial metabolism.

      Study Design:

      This proposal is for a randomized blinded pilot study on the use of rIP in patients requiring
      heart surgery.

      Study Population:

      The study will include 100 male and female patients undergoing elective heart surgery with
      cardiopulmonary bypass (CPB).

      Randomization:

      Patients will be randomized 1:1 to receive either rIP or no treatment.

      Blinding Procedures:

      The patient will be blinded as well as those performing the experimental analysis.

      Interventions:

      Remote Ischemic Preconditioning

      rIP will be induced immediately following induction of anesthesia. Four 5 minute cycles of
      lower unilateral limb ischemia and reperfusion induced tourniquet inflation to 300 mmHg will
      constitute the preconditioning stimulus.

      Blood sample collection/analysis

        1. Two cardiac biopsies (50 - 200 mg) will be collected pre-bypass and post- bypass and
           will be analyzed for gene and protein expression.

        2. Blood samples (4 mL) will be drawn immediately before induction of anesthesia, and at
           the same times as cardiac tissue samples are harvested and analyzed for gene/protein
           expression as well as at 1, 24, 48 and 72 hours post surgery. Troponin I and NT-ProBNP
           will be measured at baseline, 1, 24, 48 and 72 hours after surgery and 3 mL of blood
           will be collected for these tests. A total of 43 mL of blood will be collected per
           patient.

        3. rIP induced changes in leukocyte gene expression will be measured at the aforementioned
           time points.

      Other

      ECG assessment on post-operative day 1, 2, and 3.

      National Institute of Health stroke scale assessment will be conducted at screening and post
      operatively prior to hospital discharge.

      Each patient will receive a telephone follow-up call at 30 days post operatively to collect
      adverse events and mortality data.

      Experimental Methods:

        1. qRT-PCR will be used to measure gene expression.

        2. Immunoblotting will be used to measure protein expression
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Protection Against Ischemic Injury</measure>
    <time_frame>72 hours post operatively</time_frame>
    <description>High-sensitivity cardiac troponin T release as measured by peak hscTnT values and area-under-the-curve.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death and Cardiovascular Long-term Outcome</measure>
    <time_frame>6-month cardiovascular outcome</time_frame>
    <description>Death and re-hospitalization due to any cause including heart and renal failure and new atrial fibrillation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Remote Ischemic Preconditioning</condition>
  <condition>Myocardial Protection</condition>
  <arm_group>
    <arm_group_label>Ischemic Preconditioned Group (rIP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Cuff</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No rIP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood Pressure Cuff</intervention_name>
    <description>The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.</description>
    <arm_group_label>Ischemic Preconditioned Group (rIP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age 18 through 80 years, inclusive

          -  Scheduled for heart surgery with CPB

        Exclusion Criteria:

          -  Females of childbearing potential

          -  Emergency surgery

          -  Previous sternotomy

          -  Myocardial infarction within 48 hours prior to surgery

          -  Diabetes and/or BMI &gt;35

          -  Need for Alpha2-agonists perioperatively

          -  Peripheral Vascular Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry A Finegan, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=Remote+Ischemic+Preconditioning+Applied+during++Isoflurane+Inhalation+Provides+No+Benefit+to+the++Myocardium+of+Patients+Undergoing+On-pump+Coronary++Artery+Bypass+Graft+Surgery</url>
    <description>PubMed link</description>
  </link>
  <results_reference>
    <citation>Lucchinetti E, Bestmann L, Feng J, Freidank H, Clanachan AS, Finegan BA, Zaugg M. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection? Anesthesiology. 2012 Feb;116(2):296-310. doi: 10.1097/ALN.0b013e318242349a.</citation>
    <PMID>22222469</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 16, 2007</study_first_submitted>
  <study_first_submitted_qc>October 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2007</study_first_posted>
  <results_first_submitted>October 24, 2017</results_first_submitted>
  <results_first_submitted_qc>October 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 15, 2019</results_first_posted>
  <last_update_submitted>October 9, 2018</last_update_submitted>
  <last_update_submitted_qc>October 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Barry Finegan</investigator_full_name>
    <investigator_title>MB, FFARC, FRCPC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2 patients were withdrawn for logistical reasons</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ischemic Preconditioned Group (rIP)</title>
          <description>A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
Blood Pressure Cuff: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>No rIP - cuff placed but not used - actions by RA as if cuff inflated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ischemic Preconditioned Group (rIP)</title>
          <description>A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
Blood Pressure Cuff: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>No rIP as described for rIP group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="7"/>
                    <measurement group_id="B2" value="62" spread="10"/>
                    <measurement group_id="B3" value="61" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="27"/>
                    <count group_id="B2" value="28"/>
                    <count group_id="B3" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Protection Against Ischemic Injury</title>
        <description>High-sensitivity cardiac troponin T release as measured by peak hscTnT values and area-under-the-curve.</description>
        <time_frame>72 hours post operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Preconditioned Group (rIP)</title>
            <description>A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
Blood Pressure Cuff: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>No cuff inflation</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Protection Against Ischemic Injury</title>
          <description>High-sensitivity cardiac troponin T release as measured by peak hscTnT values and area-under-the-curve.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="266"/>
                    <measurement group_id="O2" value="231" spread="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Death and Cardiovascular Long-term Outcome</title>
        <description>Death and re-hospitalization due to any cause including heart and renal failure and new atrial fibrillation</description>
        <time_frame>6-month cardiovascular outcome</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Preconditioned Group (rIP)</title>
            <description>A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
Blood Pressure Cuff: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>No rIP - cuff placed but not used - actions by RA as if cuff inflated</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Death and Cardiovascular Long-term Outcome</title>
          <description>Death and re-hospitalization due to any cause including heart and renal failure and new atrial fibrillation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ischemic Preconditioned Group (rIP)</title>
          <description>A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff. Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
Blood Pressure Cuff: The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.</description>
        </group>
        <group group_id="E2">
          <title>No Cuff</title>
          <description>No rIP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>New Atrial Fib</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr B Finegan</name_or_title>
      <organization>University of Alb erta</organization>
      <phone>7809701302 ext 780</phone>
      <email>bfinegan@ualberta.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

